Literature DB >> 21612857

Global trends in testicular cancer incidence and mortality.

Alexandre Rosen1, Gautam Jayram, Michael Drazer, Scott E Eggener.   

Abstract

BACKGROUND: Epidemiologic studies on testicular cancer have focused primarily on European countries. Global incidence and mortality have been less thoroughly evaluated.
OBJECTIVE: Our goal was to gain a better understanding of the most recent global age-standardized incidence and mortality rates for testicular cancer and to use these values to estimate a region's health care quality. DESIGN, SETTING, AND PARTICIPANTS: Age-standardized incidence rate (ASIR) and age-standardized mortality rate (ASMR) for testicular cancer were obtained for men of all ages in 172 countries by using the GLOBOCAN 2008 database, reflecting the annual rate of cancer incidence and mortality per 100,000 men. These data were evaluated on a regional level to compare incidence and mortality rates. Global plots of these values were constructed to better visualize geographic distributions. Finally, the ratio of ASIR to ASMR was calculated as a method to assess each region's proficiency in diagnosing and effectively treating testicular cancer. MEASUREMENTS: ASIR and ASMR were analyzed by region, and each region's ratio of ASIR to ASMR was calculated. RESULTS AND LIMITATIONS: Testicular cancer ASIR is highest in Western Europe (7.8%), Northern Europe (6.7%), and Australia (6.5%). Asia and Africa had the lowest incidence (<1.0%). ASMR was highest in Central America (0.7%), western Asia (0.6%), and Central and Eastern Europe (0.6%). Mortality was lowest in North America, Northern Europe, and Australia (0.1-0.2%). The ASIR-ASMR ratio was highest in Australia (65.0%) and lowest in western Africa (1.0%). National reporting systems varied by country, and data quality may have fluctuated between regions.
CONCLUSIONS: Testicular cancer incidence remains highest in developed nations with primarily Caucasian populations. Variable ASIR-ASMR ratios suggest markedly different geographic-specific reporting mechanisms, access to care, and treatment capabilities.
Copyright © 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21612857     DOI: 10.1016/j.eururo.2011.05.004

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  40 in total

Review 1.  Cancer/testis antigens and urological malignancies.

Authors:  Prakash Kulkarni; Takumi Shiraishi; Krithika Rajagopalan; Robert Kim; Steven M Mooney; Robert H Getzenberg
Journal:  Nat Rev Urol       Date:  2012-06-19       Impact factor: 14.432

2.  In vitro study on shRNA-mediated reduction of testis developmental related gene 1 expression and its effects on the proliferation, invasion and apoptosis of NTERA-2 cells.

Authors:  Y U Gan; Jianfu Yang; Yong Wang; Zhengyu Tan; Xianzhen Jiang; Yuxin Tang
Journal:  Oncol Lett       Date:  2015-05-18       Impact factor: 2.967

3.  Three primary testicular tumours: Trials and tribulations of testicular preservation.

Authors:  Connor M Forbes; Charles Metcalfe; Nevin Murray; Peter C Black
Journal:  Can Urol Assoc J       Date:  2013 Sep-Oct       Impact factor: 1.862

Review 4.  Epidemiology of Prostate and Testicular Cancer.

Authors:  Pauline Filippou; James E Ferguson; Matthew E Nielsen
Journal:  Semin Intervent Radiol       Date:  2016-09       Impact factor: 1.513

5.  The role of spermatogenesis-associated protein 6 in testicular germ cell tumors.

Authors:  Shiwei Huo; Wenyan Du; Peng Shi; Yuexiu Si; Shengtian Zhao
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

6.  Incorporating non-biological factors into the TNM staging system for better prognostication and decision-making in testicular cancer.

Authors:  Yongqiang Huang; Haoyue Sheng; Junyu Zhang; Qi Liu; Dingwei Ye; Guohai Shi
Journal:  World J Urol       Date:  2018-12-15       Impact factor: 4.226

Review 7.  Adolescent and adult risk factors for testicular cancer.

Authors:  Katherine A McGlynn; Britton Trabert
Journal:  Nat Rev Urol       Date:  2012-04-17       Impact factor: 14.432

8.  Increase in testicular germ cell tumor incidence among Hispanic adolescents and young adults in the United States.

Authors:  Franklin L Chien; Stephen M Schwartz; Rebecca H Johnson
Journal:  Cancer       Date:  2014-07-14       Impact factor: 6.860

Review 9.  [Importance of pathology for therapy planning of testicular germ cell tumors].

Authors:  A Heidenreich; R Knüchel-Clarke; D Pfister
Journal:  Pathologe       Date:  2014-05       Impact factor: 1.011

Review 10.  Manipulating the epigenome for the treatment of urological malignancies.

Authors:  Colm J O'Rourke; Vinicius Knabben; Eva Bolton; Diarmaid Moran; Thomas Lynch; Donal Hollywood; Antoinette S Perry
Journal:  Pharmacol Ther       Date:  2013-01-24       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.